Introduction
In cancer treatment, remarkable progress has been made recently through genetic and molecular approaches. In cancer immunotherapy, a target antigen must be highly expressed only in cancer cells. The conventional immunopotentiation therapy was expected to induce an antitumor effect by immunoreaction which was activated non-specifically. On the other hand, the recent study is focused on that how we let it elicit specific immune response effectively. In particular: i) identification of cancer specific antigen and its peptide shown by human histocompatibility leukocyte antigen; HLA, ii) the development of the activation method of a T cell recognition. The target antigen of the cancer immunotherapy is needed to be highly expressed only in cancer cells and not expressed in normal cells. At present, cancer/testis (CT) antigens are considered as one of the suitable targets. The antigen groups were expressed in various kinds of cancer tissue and only in a testis and thymus, in some antiges, in the normal tissue. The MAGE gene characteristic of human melanoma is representative (1) . Testis cells have little or no expression of MHC molecules and little ability to present an antigen to T cells. Therefore, CT antigens are considered good targets for cancer immunotherapy. As for CTLs recognizing the CT antigen, they are thought to attack cancer cells selectively without attacking the testis cells which have no MHC molecule (2) .
We recently reported that mitotic centromere-associated kinesin (MCAK) was overexpressed in gastric cancer cells, mediating poor prognosis (3) , only in cancer cells and the in testis of the adult man in the normal tisssue (4) . Considering this result, we hypothesized that MCAK could be a CT antigen. MCAK is a member of the kinesin family. It is found throughout the cell and is especially concentrated at the centromeres, kinetochores and spindle poles (5 (6) (7) (8) (9) . Members of the kinesin superfamily play an important role in intracellular transport and cell division (10) . Unlike other kinesins that transport cargo, MCAK and the other members of the Kin-I subfamily of kinesins catalyze microtubule disassembly, a key aspect of normal chromosome movement (5) . Regarding the association of MCAK with cancer, MCAK was reported to be highly expressed in colon cancer tissue (11) , breast cancer (12, 13) and gastric cancer (3) . Therefore, MCAK is a suitable target antigen for cancer-specific immunotherapy.
In this study, we identified MCAK peptides, which could induce CTL, to clarify the possibility of cancer specific immunotherapy using novel cancer/testis antigen MCAK as target antigen.
Materials and methods
Cell lines. The human chronic myeloid leukemic cell line K562, colon cancer cell line RCM1, colo201, colo205, colo320DM, DLD1, WiDr, and the gastric cancer cell line NUGC3 were supplied by the Japanese Collection of Research Bioresources Cell Bank (Tokyo, Japan). The gastric cancer cell lines MKN45, KATOIII, AZ521 were obtained from the Cell Resource Center for Biomedical Research, Tohoku University. RCM1 was maintained in 45% RPMI-1640 with 45% Ham's F12, 10% fetal bovine serum. Other cell lines were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum, 100 IU/ml penicillin, and 100 μg/ml streptomycin.
Total RNA extraction. Frozen tissue specimens were homogenized in guanidium thiocyanate, and total RNA was obtained by ultracentrifugation through a cesium chloride cushion, as described previously (11) .
Quantitative real-time PCR. Total RNA was extracted from each bulk sample and cDNA was synthesized from 8.0 μg total RNA as described previously (14) . The following primers were used to amplify the MCAK: sense primer, 5'-GATGGAAGCCTGCTCTAACG-3', and antisense primer 5'-GAGCAGATTCCGCTTTGTTC-3'. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH; sense primer 5'-TTGG TATCGTGGAAGGACTCA-3' and antisense primer 5'-TG TCATCATATTTGGCAGGTTT-3') was used as an internal control. Reactions were performed in a Light Cycler system (Roche Applied Science, Indianapolis, IN) using the Light Cycler Fast Start DNA Master SYBR-Green I kit (Roche Diagnostics, Mannheim, Germany). Details of each reaction are described elsewhere (15) . Briefly, thermal cycling for all genes was initiated with a denaturation step of 95˚C for 10 min, followed by 40 cycles at 95˚C for 10 sec, 66˚C (60˚C for GAPDH) for 10 sec, and 72˚C for each optimal length (1 sec/25 bp). All calculated concentrations of target genes were divided by the amount of the endogenous reference (GAPDH) to obtain normalized MCAK expression values. Each assay was performed in triplicate. CTL induction. CTL induction in vitro was performed according to the procedure described previously (16, 17) . In brief, PBMCs of healthy donors (HLA-A * 0201 or -A * 2402) were collected by centrifugation on a Ficoll-Paque density gradient. Written informed consent was obtained from all healthy donors. PBMCs were pre-pulsed by purified peptides at a final concentration of 20 μg/ml for 2 h at 37˚C. Cells were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 100 units/ml penicillin, 100 μg/ml streptomycin, and 50 μM 2-mercaptoethanol (Wako Pure Chemical Industries, Ltd., Osaka, Japan), with the addition of keyhole limpet hemocyanin (5 μg/ml, Calbiochem-Novabiochem Co., San Diego, CA) and IL-7 (25 ng/ml; Peprotech EC Ltd., London, UK). On day three, recombinant IL-2 (Peprotech) was then added to the culture at 50 IU/ml. Responder cells were restimulated every seven days with freshly isolated autologous PBMCs that had been prepulsed with peptide and treated with mitomycin C (Kyowa Hakko Co., Ltd., Osaka, Japan). Cultures were fed with fresh medium containing IL-2 one day after stimulation. CTL activity was assessed on day 21.
Phenotypic analysis. Flow cytometric analysis of the CTLs was performed using a FACScan. The cells were stained with murine anti-human monoclonal antibodies against CD3, CD4 and CD8 (Becton-Dickinson, San Jose, CA). Isotypematched murine antibodies (Becton-Dickinson) served as negative controls.
Cytotoxicity assay. Target cells were labeled with 100 μCi of 51 Cr for 1 h at 37˚C and labeled cells were then washed and resuspended. Peptide-pulsed targets, colo205, colo320DM cells, were prepared by incubating the cells with peptides for 2 h at 37˚C and then labeling them with 51 Cr. Effector cells were placed in each well of round-bottomed microtiter plates in duplicate. Labeled target cells (1x10 4 cells/well) were incubated with various numbers of effector cells for 4 h at 37˚C. Radioactivity of the culture supernatant was measured with an automated Á counter and the percentage of specific lysis was calculated according to the following formula: (experimental 51 Cr release -spontaneous 51 Cr release)/(maximum 51 Cr release -spontaneous 51 Cr release) x 100.
Inhibition of cytotoxicity with monoclonal antibody.
Appropriate target cells were incubated with monoclonal antibodies at a final concentration of 20 μg/ml for 1 h at 4˚C prior to the assay for cytotoxicity. The monoclonal antibodies used were anti-HLA class I, CD4, CD8 and control IgG antibody (Abcam, Cambridge, UK).
Statistical evaluation. Statistical analysis was performed using a repeated measure ANOVA method when comparing the cytotoxic activity in an individual group. Differences were considered significant at p<0.05.
Results
Expression of MCAK mRNA. We analyzed the expression of MCAK mRNA in all cell lines used in this study (Fig. 1) (Fig. 1) .
Screening of peptides from MCAK.
We pulsed PBMCs obtained from healthy donors using five peptides (Tables I  and II) . After 21 days of culture, we performed a cytotoxicity assay against cancer cell lines DLD-1 (which expressed both HLA-A * 0201 and -A * 2402 and the MCAK gene) and K562 which has high cytotoxic activity for the natural killer cells. High specific cytotoxic activity and low NK activity were generated using 63: AINPELLQ (HLA-A * 0201) and 401: FFEIYNGKL (HLA-A * 2402) peptide in five peptide in the DLD-1 cell line (Fig. 2) . Table I . HLA-A * 0201 binding motif containing 9-mer peptides derived from the sequence of MCAK.
Characterization of the cytotoxic effectors.
Amino acid sequence Binding score (BIMAS) Binding score (SYFPEITHI) 288  LLLVHEPKL  134  28  375  AMASRDVFL  85  27  421  VLEDGKQQV  31  24  519  SLLALKECI  19  23  63  AINPELLQL  7 
increased after day 14. As for both, on day 21, 70% of the cells were positive for CD8 (Fig. 3) . . After 21 days of culture, the effector cells induced by using the two peptides exhibited significantly higher cytotoxicity against the peptide-pulsed colo205 and colo320DM cells than nonpulsed colo205 and colo320DM cells (Fig. 4) . 580  RYADRVKEL  528  23  404  IYNGKLFDL  300  22  324  VYRFTARPL  200  21  401  FFEIYNGKL  33  18  231  EFARMIKEF  11  17 ----------------------------------------------------------------------------------------------------- Start position indicates the number of amino acids from N-terminal of MCAK. Binding score is derived from 'BIMAS' and 'SYFPEITHI' as described in Materials and methods. (Tables I and II) , and re-stimulated with peptide-pulsed autologous PBMC two times. After 21 days, the effector cells were co-cultured with 51 Cr-labeled DLD-1 cells and K562 for 4 h and radioactivity of the culture supernatant was determined with a Á counter. significantly eliminated by the anti-HLA-class-I and -CD8 antibody. Marginal inhibition was observed when we used an anti-CD4 antibody (Fig. 6) . These results suggested that induced effectors mainly lysed target cells expressing MCAK in an HLA-class I, CD8-restricted manner.
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Discussion
MCAK is controlled by aurora kinase which has been implicated in tumorigenesis (18) . Aurora kinase encompasses . As irrelevant peptides restricted by HLA-A2, MAGE-A3/HLA-A2 peptide (FLWGPRALV), and peptide with HLA-A2402, MAGE-A3/HLA-A2402 (IMPKAGLLI) were used. Data represent the mean ± SD of cytotoxicity. There was a significant difference between cytolytic activity against colo205 pulsed with p63, colo205 pulsed with p401 cells and those against other targets (p<0.01 for all). Experiments against cells pulsed with irrelevant peptides were repeated twice, others were repeated at least four times.
three known family members, aurora-A, -B and -C. The function of aurora C is unknown, but aurora A and aurora B played an important roles in cell division. In addition, aurora-A and -B are overexpressed in a variety of tumor cell lines, suggesting their potential role in gene instability and inducing tumor progression (5). Aurora-B kinase inhibitor was considered a cancer drug target due to its induction of cytostasis and apoptosis. A phase I trial has been carried out with chronic myelogenous leukemia patients using aurora-B kinase inhibitor (19) . Aurora B is enriched at merotelic . Data represent the means ± SD of cytotoxicity. There was a significant difference between cytolytic activity against DLD-1 (both MCAK and HLA-A0201), NUGC3 (both MCAK and HLA-A2402), and those against other targets (either/both HLA and/or MCAK expression was inadequate) (p<0.01 for all). The cytotoxic activity of the CTLs was estimated after co-culture with monoclonal antibody-treated cells or non-treated cells at an E/T ratio of 10:1. Data represent the means ± SD of cytotoxicity. There was a significant difference between cytolytic activities when treated with anti-class I and anti-CD8 antibody, but not with anti-CD4 or control IgG (p<0.01 for both DLD-1 and NUGC3). Experiments using anti-class I mAb and parent cells were repeated three times, then experiments using anti-CD4, CD8 and control IgG experiments were repeated twice. attachment sites, where it regulates MCAK (20) . MCAK is regulated in its localization and microtubule depolymerization activity by Aurora B phosphorylates (23) . Overexpression of aurora B in cancer cells promotes the microtubule depoly-merization activity of MCAK, and this may promote cancer cell immortality.
In our previous study, MCAK was considered to be a CT antigen and was overexpressed in gastric cancer, suggesting the possibility of being a target gene for cancer specific immunotherapy (3) (Fig. 5) .
To determine the mechanism of immunological response in the recognition of antigen by the MCAK-reactive CTLs, anti-HLA class I monoclonal antibodies were tested for their capacity to inhibit the 51 Cr-releasing assay by MCAKspecific CTLs when the cells were cultured with DLD1 or NUGC3 cells. Cytolysis induced by MCAK-specific CTLs was significantly inhibited by anti-HLA class I and anti-CD8 monoclonal antibodies, indicating that the CTLs recognize the MCAK-derived epitopes in an HLA class I, and CD8-restricted manner (Fig. 6) . Because effector cells obtained in this study included CD4 + cells, we determined the contribution of the cytotoxic activity of CD4 + cells. Consistent with our previous studies using MAGE-A3 derived CTLs, only a marginal effect was observed (16, 17) . In this study, effector cells were generated in conditioned medium containing KLH, modified from the method of Plebanski et al (24) . Using this method, we previously identified MAGE-A3/ HLA-A24 (17), NY-ESO-1/HLA-A24 (25) , and STK31/HLA-A2 peptides (26) after generation of effector cells. KLH generates immunoreactive B cells, and CD4 + and CD8 + T cells. In this study, we were unable to obtain PBMC from cancer patients. In the next study, we shall examine the generation of CTLs from patients with cancer.
MAGE-3, NY-ESO-1, and SSX-2 are known as CT antigens that are recognized in CTL and are over-expressed in colon and gastric cancers (27, 28) . Generally, the incidence of CT antigen expression in various tumor types has a low frequency in colon and gastric cancers (29) . However, MCAK is overexpressed in gastric cancer (3), colon cancer (11) , and breast cancer (12) . It is known that the expression of the CT antigens, MAGE and NY-ESO-1, cross-over (29, 30) . This narrows the adaptation range of the cancer immunotherapy. However, in case of patients with gastric cancer, MCAK expression was observed in 28% of the cases without the expression of MAGE and NY-ESO-1 (3). Furthermore, there is a report that MCAK participates in the growth and carcinogenesis of breast cancer, and MCAK expression is high in a colon cancer cell line which is a 5-FU resistant strain (31) . MCAK immunotherapy might be effective after treatment of 5FU therapy in cancer patients.
In this study, we identified novel cancer/testis antigen MCAK peptides which could induce CTLs to lyse cancer cells in an HLA-A2-or HLA-A24-restricted manner. Our results provide evidence that this methodology to identify CT antigens is useful and MCAK is a promising target for cancer immunotherapy for colorectal, and gastric cancers.
